CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy - Slideshow

CareDx presented clinical validation data for AlloHeme, its liquid biopsy test for detecting minimal residual disease in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-cell therapy. The company outlined plans to launch AlloHeme commercially, targeting patients undergoing chimeric antigen receptor (CAR) T-cell or stem cell therapies, with a focus on improving relapse monitoring. Data reviewed highlights AlloHeme’s sensitivity and specificity in detecting early signs of disease recurrence, potentially enabling earlier intervention compared to traditional bone marrow biopsies. CareDx emphasized the test’s role in personalized medicine, aiming to integrate it into standard post-therapy monitoring protocols for hematologic malignancies by late 2026. The presentation underscored regulatory and clinical milestones, including ongoing discussions with the FDA to accelerate approval based on real-world evidence and validation studies.